Ryan T Morse

Ryan T Morse


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RMRyan T Morse
Ryan T Morse
RGRohit G. Ganju
Rohit G. Ganju
GGGregory N Gan
Gregory N Gan
YCYing Cao
Ying Cao
PNPrakash Neupane
Prakash Neupane
CLChristopher E. Lominska
Christopher E. Lominska
This study was performed to identify treatment related toxicities in older adults undergoing concurrent chemoradiotherapy for head and neck cancer and nutritional and skeletal muscle measures that might identify frailty. Imaging analysis was done with the following skeletal muscle measurements: skeletal muscle index (SMI), skeletal muscle density (SMD), and skeletal muscle gauge (SMG). Patients were dichotomized by age into younger (<70 years old, 221 patients) and older age groups (≥70 years old, 51 patients). Low SMI was more common in older patients (86.7%) compared to younger patients (51.7%, p < 0.01), as were low SMD (57.8% vs. 37.3%, p = 0.012) and low SMG (76.1% vs. 44.2%, p < 0.01), despite having similar BMIs (27.3 kg/m2 versus 27.7 kg/m2, p = 0.71). Older patients were significantly more likely to experience chemotherapy toxicity than younger patients (54.9% versus 32.3%, p < 0.01). On multivariate analysis age (p < 0.01), current smoking status (p < 0.01), and low SMI (p < 0.01) remained as significant predictors for missed chemotherapy cycles or discontinuation. Older patients were more likely to require ≥5-day radiation breaks than younger patients (27.5% versus 8.6%, p < 0.01). On multivariate analysis, age (p < 0.01), low albumin status (p = 0.03), and low SMI (p = 0.04) were identified as predictors of prolonged radiation treatment breaks. Based on the results of our study, sarcopenia may be used as an additional marker for frailty alongside traditional performance status scales.

30 September 2022 in Oral Oncology
Verified
Journal Article
Closed access
RMRyan T Morse
Ryan T Morse
BBBrian Beaty
Brian Beaty
LSLori Scanga
Lori Scanga
JBJeff Blumberg
Jeff Blumberg
SPSamip Patel
Samip Patel
BCBhisham S. Chera
Bhisham S. Chera

30 September 2020 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
RMRyan T Morse
Ryan T Morse
ASAbigail Smith
Abigail Smith
SFSharon Fitzgerald-Wolff
Sharon Fitzgerald-Wolff
KSKy Stoltzfus
Ky Stoltzfus

1 September 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
RGR.G. Ganju
R.G. Ganju
RMRyan T Morse
Ryan T Morse
MTM.J. Tennapel
M.J. Tennapel
AHA. Hoover
A. Hoover
KKK. Kakarala
K. Kakarala
CLC.E. Lominska
C.E. Lominska
Sarcopenia (decrease in skeletal muscle) is common in head and neck cancer patients and predicts poor prognosis in patients with p16-negative disease. Its impact in patients with p16-positive oropharynx cancers is unknown. Objective measures of sarcopenia include skeletal muscle index (SMI), skeletal muscle density (SMD), and skeletal muscle gauge (SMG), a novel measure which incorporates both SMI and SMD. We reviewed our institutional experience of p16-positive oropharynx cancer patients receiving concurrent chemoradiation and assessed outcomes with respect to skeletal muscle measures.

30 August 2024 in Clinical Breast Cancer
Verified
Journal Article
Closed access
RMRyan T Morse
Ryan T Morse
NBNathan W. Bean
Nathan W. Bean
JHJacob Hall
Jacob Hall
ADAllison Deal
Allison Deal
KNKirsten A. Nyrop
Kirsten A. Nyrop
DCDana L. Casey
Dana L. Casey

20 September 2024 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RMRyan T Morse
Ryan T Morse
TNTyler J. Nelson
Tyler J. Nelson
HLHannah C. Liu
Hannah C. Liu
PSPrangrawee Sangchan
Prangrawee Sangchan
BCBhargava Chitti
Bhargava Chitti
LMLoren K. Mell
Loren K. Mell